Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis

Hermann Schulz(University of Freiburg), Andreas Engert(University of Freiburg), Michael Herold(University of Freiburg), Michael Hallek(University of Cologne), M. Dreyling(LMU Klinikum), Thilo Kober(University of Freiburg), Guido Schwarzer(University of Freiburg), Julia Bohlius(Institute of Social and Preventive Medicine), Nicole Skoetz(Medical University of Vienna), Maximilian F. Reiser(Ludwig-Maximilians-Universität München), Sven Trelle(Institute of Social and Preventive Medicine)
JNCI Journal of the National Cancer Institute
April 30, 2007
10.1093/jnci/djk152
Cited by 366

Related Papers

Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
|BMJ|2020|3.2k
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
|The Lancet|2007|1.4k